Suzanne Hill

  • This book is intended to communicate current best practice in pediatric clinical pharmacology and clinical pharmacy with special consideration of the prevailing circumstances and most pressing needs in developing countries. It also addresses measures that may be taken in countries with emerging economies through organizational and political adjustments to reduce unacceptable levels of morbidity and mortality among children and pregnant women with treatable diseases.

  • "The challenge in all settings is to make the difficult decisions in a way that is defensible, justifiable, ethical, and equitable"
    So write Nick Freemantle and Suzanne Hill in their introduction to this important discussion on decision making in the reimbursement of pharmaceuticals. Based around a programme supported by the World Health Organization, chapters by leading academics involved in the research tackle such major issues as international pharmaceutical policy, tensions in licensing policies, priority setting, and relationships between the stakeholders.
    Chapters include
    Development of marketing authorisation procedures for pharmaceuticals
    Interpreting clinical evidence
    International pharmaceutical policy: health creation or wealth creation?
    Development of fourth hurdle policies around the world
    Economic modelling in drug reimbursement
    Priority setting in health care: matching decision criteria with policy objectives
    Tensions in licensing and reimbursement decisions: case of riluzole for amytrophic lateral sclerosis
    Relationship between stakeholders: managing the war of words
    Medicine and the media: good information or misleading hype?
    How to promote quality use of cost-effective medicines
    Using economic evaluation to inform health policy and reimbursement: making it happen and making it sustainable
    Pricing of pharmaceuticals
    Evaluating pharmaceuticals for health policy in low and middle income country settings.
    Besides the controversial issues there is a wealth of practical information including economic modelling and the experiences from the WHO programme, providing readers with workable examples. This is essential reading for clinical researchers in pharmaceuticals and policy makers everywhere.

empty